TEMPEST THERAPEUTICS, INC.

Consensus Tempest Therapeutics, Inc.

Stocks

TPST

US87978U2078

Biotechnology & Medical Research

Delayed Nasdaq 20:36:18 31/08/2026 +04			5-day change	1st Jan Change
1.070 ^USD	+0.94%		-2.73%	-62.72%

08-25	Tempest Therapeutics, Inc. Appoints Nicholas Rossettos as Chief Financial Officer, Effective September 1, 2026	CI
08-25	Tempest Therapeutics, Inc. Announces Executive Changes, Effective September 1, 2026	CI

Evolution of the Average Target: Tempest Therapeutics, Inc.

Evolution of the Target Price: Tempest Therapeutics, Inc.

Changes in Analyst Recommendations: Tempest Therapeutics, Inc.

1.QKa4D_VZprmGnjVqsRd6EQ6HwxP0xTVgRqQoTudivDU.MpP1UMEe9Ovr6lwI1HUsWH3vsXSitV0Mf_dAIrgg5HwwwItKtyiUw8_TYA~185e75528e82b4ec1b152d94fc40140e

Analysts' recommendations: Tempest Therapeutics, Inc.

01-22	HC Wainwright Upgrades Tempest Therapeutics to Buy From Neutral, Price Target is $11	MT
10/04/25	HC Wainwright Downgrades Tempest Therapeutics to Neutral From Buy	MT
14/03/24	Scotiabank Initiates Tempest Therapeutics With Sector Outperform Rating, Price Target is $13	MT
11/10/23	HC Wainwright Raises Price Target on Tempest Therapeutics to $47 From $35, Maintains Buy Rating	MT
23/03/23	Piper Sandler Adjusts Tempest Therapeutics' Price Target to $6 From $10, Keeps Overweight Rating	MT
15/09/22	Ladenburg Thalmann Starts Tempest Therapeutics at Buy With $8 Price Target	MT
13/05/22	HC Wainwright Adjusts Tempest Therapeutics Price Target to $35 From $51, Maintains Buy Rating	MT
28/04/22	Piper Sandler Adjusts Price Target on Tempest Therapeutics to $20 From $23, Reiterates Overweight Rating	MT
21/10/21	Tempest Therapeutics : William Blair Initiates Tempest Therapeutics at Outperform Rating	MT
13/07/21	Tempest Therapeutics : HC Wainwright Starts Tempest Therapeutics at Buy With $51 Price Target	MT
06/07/21	Tempest Therapeutics : Piper Sandler Starts Tempest Therapeutics at Overweight With $23 Price Target	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	TEMPEST THERAPEUTICS, INC.			-	-	+937.74%
	LONZA GROUP AG					+16.67%
	REVOLUTION MEDICINES, INC.					+18.87%
	IQVIA HOLDINGS INC.					+5.13%
	BEONE MEDICINES AG					+17.84%
	CELLTRION, INC.					+39.5%
	MEDPACE HOLDINGS, INC.					-3.13%
	ASCENDIS PHARMA A/S					+27.58%
	EUROFINS SCIENTIFIC SE					+0.23%
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.					-3.6%
	Average					+105.68%
	Weighted average by Cap.					+15.75%

See all sector performances

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

BUY

Number of Analysts

1

Last Close Price

1.060USD

Average target price

11.00USD

Spread / Average Target

+937.74%

High Price Target

11.00USD

Spread / Highest target

+937.74%

Low Price Target

11.00USD

Spread / Lowest Target

+937.74%

Analyst Consensus Detail

Consensus revision (last 18 months)

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

Stock Market
Stocks
TPST Stock
Consensus Tempest Therapeutics, Inc.

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Unlock them now!